Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05365659` - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas	Phase 1
Active, not recruiting	`NCT03671018` - A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma	Phase 1/Phase 2
Completed	`NCT00992446` - Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma	Phase 2
Completed	`NCT03263637` - Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies	Phase 1
Active, not recruiting	`NCT02633111` - DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Terminated	`NCT02151903` - Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL	Phase 1/Phase 2
Active, not recruiting	`NCT01919619` - Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies	Phase 2
Terminated	`NCT01874288` - A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL	Phase 1/Phase 2
Completed	`NCT02847130` - Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Suspended	`NCT03704714` - Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05053971` - Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas	Phase 1/Phase 2
Completed	`NCT03677141` - A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT02981914` - Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation	Early Phase 1
Completed	`NCT03483688` - A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects	Phase 1
Terminated	`NCT05107856` - PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies	Phase 1
Recruiting	`NCT06191887` - B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT05201248` - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma	Phase 1
Terminated	`NCT03195010` - Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia	Phase 2
Recruiting	`NCT06052826` - Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study	Phase 2
Completed	`NCT02424968` - CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma	Phase 2

NCT number	NCT04296461
Study type	Interventional
Source	UWELL Biopharma
Contact	Cheng-Yi Kuo, PhD
Phone	+886-2-26972200
Email	jerry.kuo@uwell.com.tw
Status	Recruiting
Phase	Phase 1
Start date	July 27, 2020
Completion date	December 31, 2021

Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms